Literature DB >> 27469179

Cystic Fibrosis: Microbiology and Host Response.

Edith T Zemanick1, Lucas R Hoffman2.   

Abstract

The earliest descriptions of lung disease in people with cystic fibrosis (CF) showed the involvement of 3 interacting pathophysiologic elements in CF airways: mucus obstruction, inflammation, and infection. Over the past 7 decades, our understanding of CF respiratory microbiology and inflammation has evolved with the introduction of new treatments, increased longevity, and increasingly sophisticated laboratory techniques. This article reviews the current understanding of infection and inflammation and their roles in CF lung disease. It also discusses how this constantly evolving information is used to inform current therapeutic strategies, measures and predictors of disease severity, and research priorities.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarker; Cystic fibrosis; Infection; Inflammation; Microbiology; Neutrophil

Mesh:

Substances:

Year:  2016        PMID: 27469179      PMCID: PMC4967239          DOI: 10.1016/j.pcl.2016.04.003

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  94 in total

1.  Infection prevention and control guideline for cystic fibrosis: 2013 update.

Authors:  Lisa Saiman; Jane D Siegel; John J LiPuma; Rebekah F Brown; Elizabeth A Bryson; Mary Jo Chambers; Veronica S Downer; Jill Fliege; Leslie A Hazle; Manu Jain; Bruce C Marshall; Catherine O'Malley; Suzanne R Pattee; Gail Potter-Bynoe; Siobhan Reid; Karen A Robinson; Kathryn A Sabadosa; H Joel Schmidt; Elizabeth Tullis; Jennifer Webber; David J Weber
Journal:  Infect Control Hosp Epidemiol       Date:  2014-07-01       Impact factor: 3.254

Review 2.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

3.  Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis.

Authors:  Elliott C Dasenbrook; William Checkley; Christian A Merlo; Michael W Konstan; Noah Lechtzin; Michael P Boyle
Journal:  JAMA       Date:  2010-06-16       Impact factor: 56.272

4.  Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration.

Authors:  R S Baltimore; C D Christie; G J Smith
Journal:  Am Rev Respir Dis       Date:  1989-12

5.  Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.

Authors:  Scott D Sagel; Ronald L Gibson; Julia Emerson; Sharon McNamara; Jane L Burns; Jeffrey S Wagener; Bonnie W Ramsey
Journal:  J Pediatr       Date:  2008-09-25       Impact factor: 4.406

Review 6.  Role of CFTR, Pseudomonas aeruginosa and Toll-like receptors in cystic fibrosis lung inflammation.

Authors:  Paul J Buchanan; Robert K Ernst; J Stuart Elborn; Bettina Schock
Journal:  Biochem Soc Trans       Date:  2009-08       Impact factor: 5.407

7.  Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function.

Authors:  Clement L Ren; Wayne J Morgan; Michael W Konstan; Michael S Schechter; Jeffrey S Wagener; Kathryn A Fisher; Warren E Regelmann
Journal:  Pediatr Pulmonol       Date:  2007-06

8.  Risk factors for lung function decline in a large cohort of young cystic fibrosis patients.

Authors:  Jonathan Cogen; Julia Emerson; Don B Sanders; Clement Ren; Michael S Schechter; Ronald L Gibson; Wayne Morgan; Margaret Rosenfeld
Journal:  Pediatr Pulmonol       Date:  2015-06-09

9.  Clinical outcomes associated with Staphylococcus aureus and Pseudomonas aeruginosa airway infections in adult cystic fibrosis patients.

Authors:  Heather G Ahlgren; Andrea Benedetti; Jennifer S Landry; Joanie Bernier; Elias Matouk; Danuta Radzioch; Larry C Lands; Simon Rousseau; Dao Nguyen
Journal:  BMC Pulm Med       Date:  2015-06-21       Impact factor: 3.317

10.  Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung.

Authors:  Alejandro A Pezzulo; Xiao Xiao Tang; Mark J Hoegger; Mahmoud H Abou Alaiwa; Shyam Ramachandran; Thomas O Moninger; Phillip H Karp; Christine L Wohlford-Lenane; Henk P Haagsman; Martin van Eijk; Botond Bánfi; Alexander R Horswill; David A Stoltz; Paul B McCray; Michael J Welsh; Joseph Zabner
Journal:  Nature       Date:  2012-07-04       Impact factor: 49.962

View more
  10 in total

Review 1.  Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure.

Authors:  Giulio Cabrini
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

2.  Bactericidal and Fungicidal Activity of N-Chlorotaurine Is Enhanced in Cystic Fibrosis Sputum Medium.

Authors:  Martina Gruber; Ivan Moser; Markus Nagl; Michaela Lackner
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

3.  Achromobacter xylosoxidans infection in cystic fibrosis siblings with different outcomes: Case reports.

Authors:  Mônica Cássia Firmida; Elizabeth Andrade Marques; Robson Souza Leão; Rosana Helena Vicente Pereira; Elenice Rosa Aguiar Rodrigues; Rodolpho Mattos Albano; Tania Wrobel Folescu; Vagner Bernardo; Pedro Daltro; Domenico Capone; Agnaldo José Lopes
Journal:  Respir Med Case Rep       Date:  2017-01-16

Review 4.  Mucins: the frontline defence of the lung.

Authors:  Caroline Ridley; David J Thornton
Journal:  Biochem Soc Trans       Date:  2018-08-28       Impact factor: 5.407

5.  Mucins trigger dispersal of Pseudomonas aeruginosa biofilms.

Authors:  Julia Y Co; Gerardo Cárcamo-Oyarce; Nicole Billings; Kelsey M Wheeler; Scott C Grindy; Niels Holten-Andersen; Katharina Ribbeck
Journal:  NPJ Biofilms Microbiomes       Date:  2018-10-10       Impact factor: 7.290

Review 6.  Bacterial Membrane Vesicles in Pneumonia: From Mediators of Virulence to Innovative Vaccine Candidates.

Authors:  Felix Behrens; Teresa C Funk-Hilsdorf; Wolfgang M Kuebler; Szandor Simmons
Journal:  Int J Mol Sci       Date:  2021-04-08       Impact factor: 5.923

Review 7.  The Use of Artificial Sputum Media to Enhance Investigation and Subsequent Treatment of Cystic Fibrosis Bacterial Infections.

Authors:  Aditi Aiyer; Jim Manos
Journal:  Microorganisms       Date:  2022-06-22

8.  Epidemiology of E. coli in Cystic Fibrosis Airways Demonstrates the Capacity for Persistent Infection but Not Patient-Patient Transmission.

Authors:  Conrad Izydorczyk; Barbara Waddell; Brett D Edwards; Jasper Greysson-Wong; Michael G Surette; Ranjani Somayaji; Harvey R Rabin; John M Conly; Deirdre L Church; Michael D Parkins
Journal:  Front Microbiol       Date:  2020-03-20       Impact factor: 5.640

Review 9.  Pulmonary Pathogens Adapt to Immune Signaling Metabolites in the Airway.

Authors:  Sebastián A Riquelme; Tania Wong Fok Lung; Alice Prince
Journal:  Front Immunol       Date:  2020-03-13       Impact factor: 7.561

10.  Carbapenems drive the collateral resistance to ceftaroline in cystic fibrosis patients with MRSA.

Authors:  Maria Celeste Varela; Melanie Roch; Agustina Taglialegna; Scott W Long; Matthew Ojeda Saavedra; Warren E Rose; James J Davis; Lucas R Hoffman; Rafael E Hernandez; Roberto R Rosato; Adriana E Rosato
Journal:  Commun Biol       Date:  2020-10-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.